Spyre Therapeutics, Inc.

Pharmaceutical Preparations

SYRE Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001636282 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$7.87B
88,173,762 shares Covers every share class this company has on file.
Insiders on file
4
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$83.33M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
1.06%
insider-held value divided by market capitalisation

What Spyre Therapeutics, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$0
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$155.20M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
125
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Spyre Therapeutics, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Spyre Therapeutics, Inc..
Insider Reported role Shares Value Last action
Officers 1
Scott L Burrows CFO 97,994 $8.72M S Open-market sale Sep 2, 2026 position reported
Officers who also sit on the board 2
Cameron Turtle CEO 642,540 $57.17M S Open-market sale Sep 1, 2026 position reported
Michael Thomas Henderson CEO 168,606 $15.00M S Open-market sale Jun 22, 2026 position reported
Directors 1
Jeffrey W Albers Board Member 27,360 $2.43M S Open-market sale Aug 7, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Tomas Kiselak sold 4,684,781 Spyre Therapeutics, Inc. (SYRE) shares for $399,658,667 on Jun 23, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Tomas Kiselak sold 4,684,781 Spyre Therapeutics, Inc. (SYRE) shares for $399,658,667 on Jun 23, 2026
Date Insider Transaction Shares Price Value Filing
Jun 23, 2026 Tomas Kiselak S Open-market sale 4,684,781 held after: 0 $85.31 $399,658,667 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Michael Thomas Henderson sold 20,000 Spyre Therapeutics, Inc. (SYRE) shares for $2,000,000 on Jun 22, 2026

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Michael Thomas Henderson sold 20,000 Spyre Therapeutics, Inc. (SYRE) shares for $2,000,000 on Jun 22, 2026
Date Insider Transaction Shares Price Value Filing
Jun 22, 2026 Michael Thomas Henderson S Open-market sale 20,000 held after: 68,606 $100.00 $2,000,000 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Michael Thomas Henderson sold 80,000 Spyre Therapeutics, Inc. (SYRE) shares for $5,952,050 on May 8, 2026

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Michael Thomas Henderson sold 80,000 Spyre Therapeutics, Inc. (SYRE) shares for $5,952,050 on May 8, 2026
Date Insider Transaction Shares Price Value Filing
May 8, 2026 Michael Thomas Henderson S Open-market sale 2,404 held after: 166,202 $72.57 $174,458 SEC filing ↗
May 8, 2026 Michael Thomas Henderson S Open-market sale 33,513 held after: 132,689 $73.72 $2,470,578 SEC filing ↗
May 8, 2026 Michael Thomas Henderson S Open-market sale 24,814 held after: 107,875 $74.76 $1,855,095 SEC filing ↗
May 8, 2026 Michael Thomas Henderson S Open-market sale 19,269 held after: 88,606 $75.35 $1,451,919 SEC filing ↗

Total of the rows above: $5,952,050, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 79 rows we hold, 0 are open-market purchases and 67 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Spyre Therapeutics, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Sep 2, 2026 Scott L Burrows S Open-market sale 18,232 $89.35 $1.63M SEC filing ↗
Sep 1, 2026 Scott L Burrows S Open-market sale 200 $89.04 $17.8K SEC filing ↗
Sep 1, 2026 Scott L Burrows S Open-market sale 2,016 $88.03 $177.5K SEC filing ↗
Sep 1, 2026 Scott L Burrows S Open-market sale 4,384 $87.11 $381.9K SEC filing ↗
Sep 1, 2026 Scott L Burrows S Open-market sale 900 $86.25 $77.6K SEC filing ↗
Sep 1, 2026 Scott L Burrows M Option exercise or conversion 7,500 $14.50 $108.8K SEC filing ↗
Sep 1, 2026 Cameron Turtle S Open-market sale 400 $89.07 $35.6K SEC filing ↗
Sep 1, 2026 Cameron Turtle S Open-market sale 3,700 $88.06 $325.8K SEC filing ↗
Sep 1, 2026 Cameron Turtle S Open-market sale 8,400 $87.15 $732.1K SEC filing ↗
Sep 1, 2026 Cameron Turtle S Open-market sale 2,500 $86.36 $215.9K SEC filing ↗
Aug 7, 2026 Jeffrey W Albers S Open-market sale 10,000 $104.68 $1.05M SEC filing ↗
Aug 7, 2026 Jeffrey W Albers S Open-market sale 8,000 $104.38 $835.0K SEC filing ↗
Aug 7, 2026 Jeffrey W Albers S Open-market sale 5,000 $104.47 $522.4K SEC filing ↗
Aug 7, 2026 Jeffrey W Albers M Option exercise or conversion 5,000 $10.39 $52.0K SEC filing ↗
Aug 3, 2026 Scott L Burrows S Open-market sale 100 $97.10 $9.7K SEC filing ↗
Aug 3, 2026 Scott L Burrows S Open-market sale 2,300 $96.30 $221.5K SEC filing ↗
Aug 3, 2026 Scott L Burrows S Open-market sale 5,100 $95.21 $485.6K SEC filing ↗
Aug 3, 2026 Scott L Burrows M Option exercise or conversion 7,500 $14.50 $108.8K SEC filing ↗
Aug 3, 2026 Cameron Turtle S Open-market sale 16 $97.46 $1.6K SEC filing ↗
Aug 3, 2026 Cameron Turtle S Open-market sale 1,392 $96.82 $134.8K SEC filing ↗
Aug 3, 2026 Cameron Turtle S Open-market sale 5,635 $95.93 $540.6K SEC filing ↗
Aug 3, 2026 Cameron Turtle S Open-market sale 7,157 $95.10 $680.6K SEC filing ↗
Aug 3, 2026 Cameron Turtle S Open-market sale 800 $93.97 $75.2K SEC filing ↗
Jul 1, 2026 Scott L Burrows S Open-market sale 1,725 $88.37 $152.4K SEC filing ↗
Jul 1, 2026 Scott L Burrows S Open-market sale 5,775 $87.55 $505.6K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 2 filers hold a position

Who owns Spyre Therapeutics, Inc.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 2 of the positions below were reported on filings shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in Spyre Therapeutics, Inc.

Funds, trusts and companies that disclose an ownership position in Spyre Therapeutics, Inc..
Owner Reported role Shares Filed
Fairmount Funds Management LLC Director,TenPercentOwner 4,830,177 joint
Fairmount Healthcare Fund II L.P. Director,TenPercentOwner 4,830,177 joint

See the full ownership map — every entity that files as an owner of a US public company.

Subsidiaries — 1 legal entity

Subsidiaries of Spyre Therapeutics, Inc.

1 legal entity named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries Spyre Therapeutics, Inc. names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
None. —
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Spyre Therapeutics, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Spyre Therapeutics, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.